Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024

One of the biggest investment themes in 2023 stemmed from the popularity of a new class of obesity and diabetes medications -- a market largely dominated by pharmaceutical juggernauts Eli Lilly (LLY 1.13%) and Novo Nordisk (NVO 0.44%).Novo Nordisk is the developer behind the wildly popular Ozempic, Wegovy, and Rybelsus -- three different formulations of the glucagon-like peptide 1 treatment (GLP-1) semaglutide. The success of Ozempic and its sibling treatments has helped Novo Nordisk acquire nearly 60% of t ...